OBJECTIVE: Patients with cortical dysplasia (CD) are difficult to treat because the MRI abnormality may be undetectable. This study determined whether fluorodeoxyglucose (FDG)-PET/MRI coregistration enhanced the recognition of CD in epilepsy surgery patients. METHODS: Patients from 2004-2007 in whom FDG-PET/MRI coregistration was a component of the presurgical evaluation were compared with patients from 2000-2003 without this technique. For the 2004-2007 cohort, neuroimaging and clinical variables were compared between patients with mild Palmini type I and severe Palmini type II CD. RESULTS: Compared with the 2000-2003 cohort, from 2004-2007 more CD patients were detected, most had type I CD, and fewer cases required intracranial electrodes. From 2004-2007, 85% of type I CD cases had normal non-University of California, Los Angeles (UCLA) MRI scans. UCLA MRI identified CD in 78% of patients, and 37% of type I CD cases had normal UCLA scans. EEG and neuroimaging findings were concordant in 52% of type I CD patients, compared with 89% of type II CD patients. FDG-PET scans were positive in 71% of CD cases, and type I CD patients had less hypometabolism compared with type II CD patients. Postoperative seizure freedom occurred in 82% of patients, without differences between type I and type II CD cases. CONCLUSIONS: Incorporating fluorodeoxyglucose-PET/MRI coregistration into the multimodality presurgical evaluation enhanced the noninvasive identification and successful surgical treatment of patients with cortical dysplasia (CD), especially for the 33% of patients with nonconcordant findings and those with normal MRI scans from mild type I CD.
OBJECTIVE:Patients with cortical dysplasia (CD) are difficult to treat because the MRI abnormality may be undetectable. This study determined whether fluorodeoxyglucose (FDG)-PET/MRI coregistration enhanced the recognition of CD in epilepsy surgery patients. METHODS:Patients from 2004-2007 in whom FDG-PET/MRI coregistration was a component of the presurgical evaluation were compared with patients from 2000-2003 without this technique. For the 2004-2007 cohort, neuroimaging and clinical variables were compared between patients with mild Palmini type I and severe Palmini type II CD. RESULTS: Compared with the 2000-2003 cohort, from 2004-2007 more CD patients were detected, most had type I CD, and fewer cases required intracranial electrodes. From 2004-2007, 85% of type I CD cases had normal non-University of California, Los Angeles (UCLA) MRI scans. UCLA MRI identified CD in 78% of patients, and 37% of type I CD cases had normal UCLA scans. EEG and neuroimaging findings were concordant in 52% of type I CD patients, compared with 89% of type II CD patients. FDG-PET scans were positive in 71% of CD cases, and type I CD patients had less hypometabolism compared with type II CD patients. Postoperative seizure freedom occurred in 82% of patients, without differences between type I and type II CD cases. CONCLUSIONS: Incorporating fluorodeoxyglucose-PET/MRI coregistration into the multimodality presurgical evaluation enhanced the noninvasive identification and successful surgical treatment of patients with cortical dysplasia (CD), especially for the 33% of patients with nonconcordant findings and those with normal MRI scans from mild type I CD.
Authors: Veriano Alexandre; Roger Walz; Marino M Bianchin; Tonicarlo R Velasco; Vera C Terra-Bustamante; Lauro Wichert-Ana; David Araújo; Helio R Machado; João A Assirati; Carlos G Carlotti; Antonio C Santos; Luciano N Serafini; Américo C Sakamoto Journal: Seizure Date: 2006-06-19 Impact factor: 3.184
Authors: Carlos Cepeda; Véronique M André; Michael S Levine; Noriko Salamon; Hajime Miyata; Harry V Vinters; Gary W Mathern Journal: Epilepsy Behav Date: 2006-07-27 Impact factor: 2.937
Authors: J Von Oertzen; H Urbach; S Jungbluth; M Kurthen; M Reuber; G Fernández; C E Elger Journal: J Neurol Neurosurg Psychiatry Date: 2002-12 Impact factor: 10.154
Authors: T Kral; M von Lehe; M Podlogar; H Clusmann; P Süssmann; M Kurthen; A Becker; H Urbach; J Schramm Journal: J Neurol Neurosurg Psychiatry Date: 2007-02-07 Impact factor: 10.154
Authors: Walter J Hader; Mark Mackay; Hiroshi Otsubo; Shiro Chitoku; Shelly Weiss; Lawrence Becker; O Carter Snead; James T Rutka Journal: J Neurosurg Date: 2004-02 Impact factor: 5.115
Authors: C Mellerio; M-A Labeyrie; F Chassoux; C Daumas-Duport; E Landre; B Turak; F-X Roux; J-F Meder; B Devaux; C Oppenheim Journal: AJNR Am J Neuroradiol Date: 2012-05-03 Impact factor: 3.825
Authors: Carlos Cepeda; Jane Y Chen; Joyce Y Wu; Robin S Fisher; Harry V Vinters; Gary W Mathern; Michael S Levine Journal: Neurobiol Dis Date: 2013-10-10 Impact factor: 5.996
Authors: Zhong I Wang; Andreas V Alexopoulos; Stephen E Jones; Imad M Najm; Aleksandar Ristic; Chong Wong; Richard Prayson; Felix Schneider; Yosuke Kakisaka; Shuang Wang; William Bingaman; Jorge A Gonzalez-Martinez; Richard C Burgess Journal: Ann Neurol Date: 2014-05-16 Impact factor: 10.422